Boston Scientific (NYSE:BSX) Issues Q1 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.780-0.800 for the period, compared to the consensus EPS estimate of 0.790. The company issued revenue guidance of $5.1 billion-$5.2 billion, compared to the consensus revenue estimate of $5.2 billion. Boston Scientific also updated its FY 2026 guidance to 3.430-3.490 EPS.

Boston Scientific Stock Performance

Shares of BSX stock traded down $13.79 on Wednesday, hitting $77.83. 49,699,961 shares of the stock were exchanged, compared to its average volume of 14,320,365. Boston Scientific has a one year low of $75.00 and a one year high of $109.50. The firm’s 50 day moving average is $94.89 and its two-hundred day moving average is $99.29. The firm has a market capitalization of $115.38 billion, a PE ratio of 41.76, a P/E/G ratio of 1.63 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business earned $0.70 earnings per share. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Oppenheimer dropped their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. TD Cowen reissued a “buy” rating on shares of Boston Scientific in a report on Monday. Citigroup reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, January 14th. Barclays cut their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Truist Financial decreased their target price on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $123.26.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 191,105 shares of company stock worth $18,067,697 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $0.80 vs. $0.78 consensus and revenue of ~$5.29B with reported sales up ~15.9% year-over-year, showing continued top-line momentum. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Organic growth and operating metrics looked healthy (organic sales ~12.7%, solid net margin and ROE), confirming underlying demand across many franchises. Boston Scientific posts Q4 beats as sales rise 16%
• Neutral Sentiment: Street sentiment remains mixed-to-positive on fundamentals: most analysts still carry Buy/Overweight ratings and several price targets remain well above current levels — offering support over the medium term. Boston Scientific Gears Up For Q4 Print; Here Are The Recent Forecast Changes
• Negative Sentiment: Management issued soft 2026 guidance: FY EPS $3.430–3.490 (roughly at/below consensus) and revenue guidance $22.2–22.4B (bottom of/just below Street expectations), which triggered the sharp immediate sell-off as investors priced in slower growth. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (EP) revenues came in light relative to expectations and were cited as a key underperformer, increasing near-term execution risk for one of the company’s higher-growth franchises. Boston Scientific (BSX) Stock: Why Shares Drop 8% Despite Earnings Beat
• Negative Sentiment: Additional selling pressure from a large insider sale (CEO Michael Mahoney sold ~160,901 shares) and unusually high put-option volume suggest elevated near-term bearish positioning. Insider Selling: Boston Scientific CEO Sells 160,901 Shares

Institutional Trading of Boston Scientific

Hedge funds have recently added to or reduced their stakes in the business. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter valued at $26,000. Pin Oak Investment Advisors Inc. bought a new position in shares of Boston Scientific in the 3rd quarter worth about $41,000. Johnson Financial Group Inc. lifted its position in Boston Scientific by 196.4% during the 3rd quarter. Johnson Financial Group Inc. now owns 735 shares of the medical equipment provider’s stock valued at $72,000 after acquiring an additional 487 shares during the period. Seldon Capital LP bought a new stake in Boston Scientific during the second quarter worth about $208,000. Finally, Victory Financial Group LLC increased its stake in shares of Boston Scientific by 14.3% during the third quarter. Victory Financial Group LLC now owns 2,216 shares of the medical equipment provider’s stock valued at $216,000 after purchasing an additional 278 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.